Human recombinant BDNF (Sigma, St. Louis, Missouri, USA) was diluted in sterile water and injected at a dose of 300 ng into the left lateral ventricle of mice (AP: −0.5 mm, L: −1.6 mm and DV: 2 mm; [59 ]). Before central drug administration, the animals were anesthetized for 20–30 s with diethyl ether. Sterile water was injected as a control (sham group). The volume of introcerebroventricularly administered solutions was 5mkl.
5-HT1A receptor agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin, Research Biochemicals Inc., Wayland, Massachusetts, USA) was dissolved in saline and given intraperitoneally at a dose of 1.0 mg/kg for the estimation of 5-HT1A receptor functionality. The selectivity of 8-OH-DPAT for the 5-HT1A receptor was confirmed earlier by data that showed that blockading 5-HT7 receptors by the selective antagonist SB269970 had no effect on hypothermia evoked by the administration of 8-OH-DPAT [60 (link)].
5-HT2A receptor agonist DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, Sigma, St. Louis, Missouri, USA) was dissolved in saline and administered intraperitoneally at a dose of 1 mg/kg to study the functionality of the 5-HT2A receptor.
5-HT1A receptor agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin, Research Biochemicals Inc., Wayland, Massachusetts, USA) was dissolved in saline and given intraperitoneally at a dose of 1.0 mg/kg for the estimation of 5-HT1A receptor functionality. The selectivity of 8-OH-DPAT for the 5-HT1A receptor was confirmed earlier by data that showed that blockading 5-HT7 receptors by the selective antagonist SB269970 had no effect on hypothermia evoked by the administration of 8-OH-DPAT [60 (link)].
5-HT2A receptor agonist DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, Sigma, St. Louis, Missouri, USA) was dissolved in saline and administered intraperitoneally at a dose of 1 mg/kg to study the functionality of the 5-HT2A receptor.